

Eugene Braunwald

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4058237/eugene-braunwald-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

376
papers

57,363
citations

94
h-index

237
g-index

406
ext. papers

66,901
ext. citations

13.7
avg, IF

7.73
L-index

#	Paper	IF	Citations
376	Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.. <i>Journal of the American Heart Association</i> , 2022 , e022733	6.3	1
375	Gliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022 , 386, 2024-2034	59.2	6
374	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	7
373	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	16.7	5
372	Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. <i>JAMA Cardiology</i> , 2021 ,	16.2	7
371	SGLT2 inhibitors: the statins of the 21st century. <i>European Heart Journal</i> , 2021 ,	9.5	8
370	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1499-1507	15.1	4
369	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021 , 42, 1698-1708	9.5	11
368	The Birth of Cardiology: The Golden Decade. <i>European Heart Journal</i> , 2021 , 42, 1650-1651	9.5	0
367	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1197-1207	15.1	10
366	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021 , 23, 1040-1048	12.3	29
365	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021 , 86, 294-300	2.2	3
364	Transseptal left heart catheterization: birth, death, and resurrection. <i>European Heart Journal</i> , 2021 , 42, 2327-2328	9.5	
363	Reflections on Hypertrophic Cardiomyopathy. <i>European Heart Journal</i> , 2021 , 42, 2969-2970	9.5	
362	Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2822-2845	15.1	4
361	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58'634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f40-f49	6.4	5
360	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021 , 143, 470-478	16.7	13

359	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 140-149	7	8
358	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , 2021 , 143, 685-695	16.7	3
357	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003006	5.2	1
356	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007034	7.6	8
355	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021 , 143, 673-684	16.7	2
354	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021 , 10, e017008	6	6
353	Cardiology in 2021. <i>European Heart Journal</i> , 2021 , 42, 959	9.5	1
352	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021 , 42, 4612-4613	9.5	1
351	A new initiative of the European Heart Journal: the Desmond Julian Award. <i>European Heart Journal</i> , 2021 , 42, 3894-3895	9.5	0
350	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021 , 27, 1818-1824	50.5	7
349	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020446	6	1
348	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2573-2581	14.6	0
347	Heart failure with preserved ejection fraction: a stepchild no more!. <i>European Heart Journal</i> , 2021 , 42, 3900-3901	9.5	2
346	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006511	5.8	1
345	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 1637-1643	40	62
344	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. <i>JACC: CardioOncology</i> , 2020 , 2, 385-396	3.8	0
343	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020 , 41, 3255-3268	9.5	20
342	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 789-799	7.9	19

341	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
340	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1095-1106	15.1	12
339	Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. <i>JAMA Network Open</i> , 2020 , 3, e1921669	10.4	7
338	Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 422-434	15.1	120
337	Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 435-447	15.1	38
336	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020 , 304, 185-191	3.2	13
335	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2020 ,	3.9	5
334	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020 , 26, 371-380	3.3	10
333	Atrial Failure as a Clinical Entity: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 222-232	15.1	82
332	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020 , 41, 1625-1632	9.5	19
331	Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). <i>American Journal of Cardiology</i> , 2020 , 125, 661-669	3	2
330	Initiation of Angiotensin-Nepriylsin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. <i>JAMA Cardiology</i> , 2020 , 5, 202-207	16.2	29
329	Angiotensin Receptor-Nepriylsin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1034-1048	15.1	19
328	Angiotensin-Nepriylsin Inhibition in Black Americans: Data From the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 859-866	7.9	4
327	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020 , 8, 834-843	7.9	6
326	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020 , 5, 1255-1262	16.2	12
325	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020 , 5, 1236-1244	16.2	15
324	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 140, 1569-1577	16.7	57

323	In Memoriam John Ross Jr, MD. <i>JAMA Cardiology</i> , 2019 , 4, 967	16.2	1
322	Diabetes, heart failure, and renal dysfunction: The vicious circles. <i>Progress in Cardiovascular Diseases</i> , 2019 , 62, 298-302	8.5	61
321	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 200-206	6.4	17
320	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019 , 139, 2285-2288	16.7	78
319	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 176-185	4.3	13
318	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. <i>Cardiac Failure Review</i> , 2019 , 5, 27-30	4.2	4
317	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019 , 74, 597-605	8.5	6
316	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 846-854	16.2	40
315	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019 , 30, 847-849	24.6	21
314	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019 , 140, 1792-1801	16.7	8
313	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019 , 21, 1571-1579	12.3	21
312	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 3013-3022	15.1	30
311	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019 , 12, e006231	7.6	5
310	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019 , 40, 1518-1527	9.5	34
309	Angiotensin-Nepriylsin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019 , 380, 539-548	59.2	446
308	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019 , 139, 760-771	16.7	54
307	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019 , 21, 306-312	3.9	3
306	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019 , 40, 1541-1550	9.5	53

305	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005041	5.8	8
304	Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 145-152	3	16
303	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 186-193	4.3	9
302	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018 , 24, 255-265	3.3	22
301	André Cournaud, Bellevue's Cardiopulmonary Laboratory, and Research on Heart Failure. <i>Annals of the American Thoracic Society</i> , 2018 , 15, S12-S14	4.7	
300	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 473-480	16.2	21
299	Aortic Stenosis: Then and Now. <i>Circulation</i> , 2018 , 137, 2099-2100	16.7	23
298	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 489-496	15.1	41
297	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018 , 257, 102-107	3.2	14
296	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation</i> , 2018 , 137, 1571-1582	16.7	198
295	Rationale and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide (NT-pro-BNP) in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018 , 198, 145-151	4.9	42
294	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1001-1008	7	11
293	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018 , 137, 684-692	16.7	10
292	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1845-1855	15.1	121
291	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018 , 122, 1451-1458	3	1
290	Cell-Based Therapy in Cardiac Regeneration: An Overview. <i>Circulation Research</i> , 2018 , 123, 132-137	15.7	40
289	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
288	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e003998	5.8	20

287	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018 , 122, 1459-1464	3	13
286	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". <i>Circulation</i> , 2018 , 137, 2662-2663	16.7	
285	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1764-1773	27.4	128
284	Treatment of Hypertension: Addressing a Global Health Problem. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1751-1752	27.4	23
283	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018 , 7, e009260	6	7
282	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1896-1901	3	12
281	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 934-943	18.1	58
280	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1466-1475	15.1	8
279	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018 , 39, 3810-3820	9.5	18
278	Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 129-136	15.1	7
277	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018 , 138, 1963-1973	16.7	23
276	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 164-172	4.3	7
275	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017 , 38, 888-896	9.5	29
274	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017 , 11, e005418	6.4	94
273	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	5
272	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 911-921	15.1	111
271	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. <i>American Heart Journal</i> , 2017 , 187, 145-155	4.9	33
270	Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	44

269	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1958-1966	27.4	201
268	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	7
267	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	37
266	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. <i>Circulation: Heart Failure</i> , 2017 , 10, e003878	7.6	29
265	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1372-1382	15.1	87
264	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. <i>JAMA Cardiology</i> , 2017 , 2, 547-555	16.2	92
263	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1549-1559	15.1	36
262	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017 , 63, 307-315	5.5	16
261	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation</i> , 2017 , 136, 2440-2450	16.7	67
260	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1217-1227	59.2	562
259	Cardiomyopathies: An Overview. <i>Circulation Research</i> , 2017 , 121, 711-721	15.7	66
258	Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. <i>Circulation Research</i> , 2017 , 121, 749-770	15.7	417
257	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1368-1375	15.1	50
256	Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 950-958	16.2	114
255	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	25
254	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017 , 40, 69-76	14.6	162
253	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now. <i>American Journal of Medicine</i> , 2017 , 130, 119-123	2.4	14
252	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016 , 37, 390-9	9.5	232

251	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2016 , 37, 378-85	9.5	31
250	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016 , 37, 3576-3584	9.5	55
249	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , 2016 , 134, 861-71	16.7	34
248	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	79
247	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016 , 134, 304-13	16.7	102
246	Updates on Acute Coronary Syndrome: A Review. <i>JAMA Cardiology</i> , 2016 , 1, 718-30	16.2	70
245	Circulation : The Beat Goes On. <i>Circulation</i> , 2016 , 134, 6-8	16.7	1
244	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016 , 134, 24-36	16.7	174
243	Treatment of Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 2284-2285	9.2	11
242	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , 2016 , 1, 425-32	16.2	70
241	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016 , 129, 850-857.e2	2.4	40
240	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). <i>American Journal of Cardiology</i> , 2016 , 117, 1055-8	3	4
239	Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist. <i>JAMA Cardiology</i> , 2016 , 1, 7-8	16.2	22
238	Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure. <i>European Heart Journal</i> , 2016 , 37, 745-6	9.5	3
237	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1145-1154	15.1	82
236	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1145-1154	4.9	13
235	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016 , 37, 1133-42	9.5	103
234	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016 , 129, 340.e1-8	2.4	27

233	Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. <i>JACC: Heart Failure</i> , 2016 , 4, 923-931	7.9	26
232	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	42
231	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". <i>Circulation</i> , 2016 , 133, e463	16.7	
230	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016 , 39, 1329-37	14.6	11
229	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	144
228	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2719-2728	15.1	225
227	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2732-2740	15.1	141
226	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	29
225	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 537-44	5.8	22
224	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1169-1178	15.1	99
223	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1289-97	27.4	614
222	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 999-1006	16.2	45
221	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 500-8	27.4	327
220	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Stroke</i> , 2016 , 47, 2075-82	6.7	57
219	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <i>European Journal of Heart Failure</i> , 2016 , 18, 1153-61	12.3	59
218	Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , 2016 , 4, 726-35	7.9	27
217	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
216	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 431-40	4.3	13

215	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015 , 385, 2280-7	40	126
214	The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1029-41	15.1	99
213	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015 , 17, 32-7	3.9	40
212	Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 245-52	7.9	39
211	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
210	Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. <i>Diabetes Care</i> , 2015 , 38, 1145-53	14.6	61
209	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015 , 132, e121-2	16.7	45
208	Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. <i>Circulation</i> , 2015 , 132, 1224-33	16.7	189
207	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. <i>Circulation</i> , 2015 , 132, 1871-9	16.7	30
206	The war against heart failure: the Lancet lecture. <i>Lancet, The</i> , 2015 , 385, 812-24	40	478
205	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015 , 372, 2387-97	59.2	2371
204	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 1470-7	9.5	42
203	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015 , 385, 2288-95	40	275
202	Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. <i>JACC: Heart Failure</i> , 2015 , 3, 97-107	7.9	75
201	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014 , 167, 437-444.e5	4.9	74
200	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014 , 383, 955-62	40	2823
199	The year in acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 201-14	15.1	13
198	Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. <i>New England Journal of Medicine</i> , 2014 , 371, 2155-66	59.2	1256

197	Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 604-12	5	36
196	Fondation Leducq. <i>Circulation Research</i> , 2014 , 115, 419-22	15.7	1
195	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 576-84	15.1	35
194	Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. <i>Circulation: Heart Failure</i> , 2014 , 7, 580-9	7.6	28
193	Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1297-305	3	8
192	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014 , 168, 205-12.e1	4.9	83
191	The ten advances that have defined modern cardiology. <i>Trends in Cardiovascular Medicine</i> , 2014 , 24, 179-83	6.3	8
190	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014 , 35, 1457-65	9.5	130
189	Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2309-17	15.1	37
188	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1006-15	27.4	285
187	Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 789-90	27.4	42
186	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. <i>Stroke</i> , 2014 , 45, 2372-8	6.7	43
185	GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. <i>Circulation: Heart Failure</i> , 2014 , 7, 673-9	7.6	33
184	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2013 , 369, 1317-26	59.2	2459
183	Unstable angina: is it time for a requiem?. <i>Circulation</i> , 2013 , 127, 2452-7	16.7	133
182	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2013 , 369, 2093-104	59.2	3215
181	Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 242-251	15.1	29
180	Research advances in heart failure: a compendium. <i>Circulation Research</i> , 2013 , 113, 633-45	15.7	54

179	Heart failure. <i>JACC: Heart Failure</i> , 2013 , 1, 1-20	7.9	481
178	What future does the pharmaceutical industry have in the cardiovascular world?. <i>European Heart Journal</i> , 2013 , 34, 943-4	9.5	1
177	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2533-43	27.4	322
176	Burton E. Sobel: 1937-2013. <i>Circulation</i> , 2013 , 128, 188-189	16.7	
175	Cardiovascular science: opportunities for translating research into improved care. <i>Journal of Clinical Investigation</i> , 2013 , 123, 6-10	15.9	17
174	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 144, 762-70	1.5	9
173	The treatment of acute myocardial infarction: the Past, the Present, and the Future. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012 , 1, 9-12	4.3	35
172	Unstable angina and non-ST elevation myocardial infarction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 924-32	10.2	37
171	Rivaroxaban in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 9-19	59.2	1357
170	Vorapaxar in the secondary prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2012 , 366, 1404-13	59.2	694
169	The rise of cardiovascular medicine. <i>European Heart Journal</i> , 2012 , 33, 838-45, 845a	9.5	34
168	Hypertrophic cardiomyopathy: The first century 1869-1969. <i>Global Cardiology Science & Practice</i> , 2012 , 2012, 5	0.7	3
167	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2342-54	15.1	6
166	Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011 , 162, 613-619.e1	4.9	69
165	Clinical efforts to reduce myocardial infarct size--the next step. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011 , 16, 349-53	2.6	17
164	HMG CoA reduction in patients with average cholesterol concentrations. <i>Clinical Chemistry</i> , 2011 , 57, 1072-3	5.5	2
163	Response to Letter Regarding Article, Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TROPIC-TIMI 38). <i>Circulation</i> , 2010 , 122, 1035-41	16.7	1
162	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective anticoagulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). <i>American Heart Journal</i> , 2010 , 160, 685-91	4.9	377

161	Adventures in cardiovascular research. <i>Circulation</i> , 2009 , 120, 170-80	16.7	18
160	Hypertrophic cardiomyopathy: the early years. <i>Journal of Cardiovascular Translational Research</i> , 2009 , 2, 341-8	3.3	13
159	Biomarkers in heart failure. Preface. <i>Heart Failure Clinics</i> , 2009 , 5, xiii-xiv	3.3	11
158	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet, The</i> , 2009 , 374, 989-997	40	531
157	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1095-103	15.1	7
156	Summary of Issues Emanating from the Workshop on Congestive Heart Failure. <i>Artificial Organs</i> , 2008 , 6, 342-344	2.6	
155	The management of heart failure: the past, the present, and the future. <i>Circulation: Heart Failure</i> , 2008 , 1, 58-62	7.6	25
154	JACC: Cardiovascular Interventions: the end of the beginning. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 1-2	5	16
153	Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 128-35	3.3	1
152	Investigating the mechanisms of hyporesponse to antiplatelet approaches. <i>Clinical Cardiology</i> , 2008 , 31, 121-7	3.3	7
151	Assessing the current role of platelet function testing. <i>Clinical Cardiology</i> , 2008 , 31, 110-6	3.3	24
150	Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. <i>Clinical Cardiology</i> , 2008 , 31, 12-9	3.3	9
149	The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 117-20	3.3	27
148	Antiplatelet therapy and platelet function testing. Introduction. <i>Clinical Cardiology</i> , 2008 , 31, 11	3.3	2
147	Antiplatelet therapy and platelet function testing. <i>Clinical Cardiology</i> , 2008 , 31, 136	3.3	5
146	Biomarkers in heart failure. <i>New England Journal of Medicine</i> , 2008 , 358, 2148-59	59.2	923
145	The American Society for Clinical Investigation, 1952--1975: a personal perspective. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1228-30	15.9	2
144	Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2007 , 357, 2001-15	59.2	4824

143	Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1775-83	27.4	372
142	Reducing myocardial injury by minimizing imbalance between oxygen supply and demand. <i>Anesthesiology</i> , 2007 , 107, 161-3	4.3	1
141	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1386-95	15.1	3
140	Epilogue: what do clinicians expect from imagers?. <i>Journal of the American College of Cardiology</i> , 2006 , 47, C101-3	15.1	59
139	The year in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 386-95	15.1	4
138	Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1411-6	15.1	252
137	The year in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 906-19	15.1	30
136	Cardiology: how did we get here, where are we today and where are we going?. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 1015-7	3.8	4
135	Intensive versus moderate lipid lowering with statins after acute coronary syndromes. <i>New England Journal of Medicine</i> , 2004 , 350, 1495-504	59.2	3769
134	Age and Routine Invasive Management of Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2004 , 141, 967	8	
133	Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. <i>Circulation</i> , 2003 , 108, III28-37	16.7	34
132	The Simon Dack lecture. Cardiology: the past, the present, and the future. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 2031-41	15.1	34
131	Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. <i>American Journal of Cardiology</i> , 2002 , 90, 821-6	3	15
130	Contemporary evaluation and management of hypertrophic cardiomyopathy. <i>Circulation</i> , 2002 , 106, 1312-6	16.7	136
129	Hypertrophic cardiomyopathy--the benefits of a multidisciplinary approach. <i>New England Journal of Medicine</i> , 2002 , 347, 1306-7	59.2	11
128	Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2001 , 53, 6-11	2.7	7
127	Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. <i>Circulation</i> , 2001 , 103, 2550-4	16.7	366
126	Changing the practice of cardiovascular medicine. <i>Atherosclerosis Supplements</i> , 2001 , 2, 27-30	1.7	3

125	Results of the Treat Angina With Aggrastat and Determine the Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI 18) Trial: A Comparison of Invasive Versus Conservative Strategy in Patients With Unstable Angina and NonST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2000 , 102, 2672-2672	16.7	4
124	TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. <i>Circulation</i> , 2000 , 102, 2031-7	16.7	1067
123	A classification of unstable angina revisited. <i>Circulation</i> , 2000 , 102, 118-22	16.7	280
122	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 321-323	5.1	
121	Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. <i>Circulation</i> , 1997 , 95, 1981-2	16.7	24
120	The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. <i>New England Journal of Medicine</i> , 1996 , 335, 1001-9	59.2	6057
119	Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 1996 , 3, 117-125	5.1	24
118	Morning resistance to thrombolytic therapy. <i>Circulation</i> , 1995 , 91, 1604-6	16.7	36
117	Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988 , 38, 303-12	4.7	5
116	Fraud and other matters?. <i>Nature</i> , 1987 , 328, 196-196	50.4	
115	Effects of chronic heart failure on the inotropic response of the right ventricle of the conscious dog to a cardiac glycoside and to tachycardia. <i>Circulation</i> , 1974 , 50, 728-34	16.7	21
114	Assessment of left ventricular performance in man. Instantaneous tension-velocity-length relations obtained with the aid of an electromagnetic velocity catheter in the ascending aorta. <i>Circulation</i> , 1973 , 47, 924-35	16.7	36
113	Protection of the Ischemic Myocardium. <i>Hospital Practice (1995)</i> , 1973 , 8, 61-74	2.2	11
112	Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. <i>Circulation</i> , 1971 , 44, 47-58	16.7	208
111	Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. <i>Journal of Clinical Investigation</i> , 1970 , 49, 1007-15	15.9	112
110	Circulatory effects of electrical stimulation of the carotid sinus nerves in man. <i>Circulation</i> , 1969 , 40, 269-76.7	76	
109	Partition of blood flow to the cutaneous and muscular beds of the forearm at rest and during leg exercise in normal subjects and in patients with heart failure. <i>Circulation Research</i> , 1969 , 24, 799-806	15.7	128
108	Mechanochemistry of cardiac muscle. IV. Utilization of high-energy phosphates in experimental heart failure in cats. <i>Circulation Research</i> , 1969 , 24, 313-20	15.7	15

107	Effects of heart failure, ventricular hypertrophy, and alterations in the thyroid state on the contractility of isolated cardiac muscle. <i>Annals of the New York Academy of Sciences</i> , 1969 , 156, 379-86	6.5	6
106	Operative treatment in idiopathic hypertrophic subaortic stenosis. Techniques, and the results of preoperative and postoperative clinical and hemodynamic assessments. <i>Circulation</i> , 1968 , 37, 589-96	16.7	105
105	Augmented sympathetic neurotransmitter activity in the peripheral vascular bed of patients with congestive heart failure and cardiac norepinephrine depletion. <i>Circulation</i> , 1968 , 38, 629-34	16.7	72
104	Contractile state of the left ventricle in man: instantaneous tension-velocity-length relations in patients with and without disease of the left ventricular myocardium. <i>Circulation Research</i> , 1968 , 22, 451-63	15.7	246
103	Integrity of energy stores in cat papillary muscle. Effect of changes in temperature and frequency of contraction on high energy phosphate stores. <i>Circulation Research</i> , 1968 , 22, 213-9	15.7	20
102	Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis. <i>Circulation</i> , 1968 , 37, 8-14	16.7	141
101	Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. <i>Circulation</i> , 1968 , 37, 759-88	16.7	423
100	Effects of acute valvular regurgitation on the oxygen consumption of the canine heart. <i>Circulation Research</i> , 1968 , 23, 33-43	15.7	38
99	Severe Mitral Regurgitation Following Acute Myocardial Infarction and Ruptured Papillary Muscle. <i>Circulation</i> , 1968 , 37,	16.7	4
98	Chapter 4: Deaths Related to Cardiac Catheterization. <i>Circulation</i> , 1968 , 37,	16.7	10
97	Chapter 17: Transseptal Left Heart Catheterization. <i>Circulation</i> , 1968 , 37,	16.7	5
96	Chapter 18: Percutaneous Left Ventricular Puncture. <i>Circulation</i> , 1968 , 37,	16.7	3
95	Aortic stenosis. <i>Circulation</i> , 1968 , 38, 61-7	16.7	730
94	Characterization of the circulatory response to maximal upright exercise in normal subjects and patients with heart disease. <i>Circulation</i> , 1967 , 35, 1049-62	16.7	122
93	The effects of mitral regurgitation on the pattern of instantaneous aortic blood flow. Clinical and experimental observations. <i>Circulation</i> , 1967 , 36, 45-53	16.7	23
92	Effects of frequency of contraction and ionic environment on the responses of heart muscle to acetylcholine. <i>Circulation Research</i> , 1967 , 21, 573-82	15.7	25
91	Significance of an atrial gallop sound in mitral regurgitation. A clue to the diagnosis of ruptured chordae tendineae. <i>Circulation</i> , 1967 , 35, 112-8	16.7	40
90	Interactions between changes in the intensity and duration of the active state in the characterization of inotropic stimuli on heart muscle. <i>Circulation Research</i> , 1967 , 21, 857-67	15.7	42

89	Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure. <i>Circulation Research</i> , 1967 , 21, 365-374	15.7	106
88	Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. <i>Circulation</i> , 1967 , 35, 847-51	16.7	134
87	Physiological differences between the effects of neuronally released and bloodborne norepinephrine on beta adrenergic receptors in the arterial bed of the dog. <i>Circulation Research</i> , 1967 , 21, 217-27	15.7	59
86	Prosthetic replacement of the mitral valve. Preoperative and postoperative clinical and hemodynamic assessments in 100 patients. <i>Circulation</i> , 1967 , 35, 962-79	16.7	95
85	Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. <i>Circulation Research</i> , 1967 , 21, 341-54	15.7	441
84	Clinical and hemodynamic appraisal of beta adrenergic blocking drugs. <i>Annals of the New York Academy of Sciences</i> , 1967 , 139, 952-67	6.5	24
83	Combined prosthetic replacement of the mitral and aortic valves. Preoperative and postoperative hemodynamic studies at rest and the left ventricular response to muscular exercise. <i>Circulation</i> , 1967 , 35, 115-23	16.7	3
82	Circulatory Effects of Acute Expansion of Blood Volume:. <i>Circulation Research</i> , 1966 , 19, 26-32	15.7	64
81	The assessment of operative results in congenital heart disease by intraoperative indicator-dilution curves. <i>Circulation</i> , 1966 , 33, 263-9	16.7	7
80	Effects of changes in body position on the severity of obstruction to left ventricular outflow in idiopathic hypertrophic subaortic stenosis. <i>Circulation</i> , 1966 , 33, 374-82	16.7	25
79	Ligation of the main pulmonary artery and systemic-pulmonary arterial anastomosis. A new palliative operation for complete transposition of the great arteries. <i>Circulation</i> , 1966 , 34, 55-60	16.7	3
78	Studies on digitalis. XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart. <i>Circulation</i> , 1966 , 34, 532-9	16.7	95
77	The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. <i>Circulation</i> , 1966 , 34, 558-78	16.7	149
76	Left ventricular performance during muscular exercise in patients with and without cardiac dysfunction. <i>Circulation</i> , 1966 , 34, 597-608	16.7	137
75	Reduction of the Cardiac Response to Postganglionic Sympathetic Nerve Stimulation in Experimental Heart Failure. <i>Circulation Research</i> , 1966 , 19, 51-56	15.7	107
74	Myocardial high energy phosphate stores in acutely induced hypoxic heart failure. <i>Circulation Research</i> , 1966 , 19, 221-9	15.7	62
73	Acute severe mitral regurgitation secondary to ruptured chordae tendineae: clinical, hemodynamic, and pathologic considerations. <i>Circulation</i> , 1966 , 33, 58-70	16.7	131
72	Alterations in regional pulmonary blood flow in mitral valve disease studied by radioisotope scanning. A simple nontraumatic technique for estimation of left atrial pressure. <i>Circulation</i> , 1966 , 34, 363-76	16.7	87

71	Determinants of atrial contractile force in the intact heart. <i>American Journal of Physiology</i> , 1965 , 209, 1061-8		95
70	Velocity of contraction as a determinant of myocardial oxygen consumption. <i>American Journal of Physiology</i> , 1965 , 209, 919-27		292
69	Mechanism of increase of myocardial oxygen uptake produced by catecholamines. <i>American Journal of Physiology</i> , 1965 , 209, 913-8		72
68	The incidence and management of "medical" complications following cardiac operations. <i>Circulation</i> , 1965 , 32, 608-19	16.7	45
67	Mechanism of norepinephrine depletion in experimental heart failure produced by aortic constriction in the guinea pig. <i>Circulation Research</i> , 1965 , 17, 312-21	15.7	128
66	AN INTRINSIC ADRENERGIC VASODILATOR MECHANISM IN THE CORONARY VASCULAR BED OF THE DOG. <i>Circulation Research</i> , 1965 , 16, 376-82	15.7	80
65	The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. <i>Circulation</i> , 1965 , 32, 755-66	16.7	389
64	A METHOD FOR THE DETECTION AND QUANTIFICATION OF IMPAIRED SODIUM EXCRETION. RESULTS OF AN ORAL SODIUM TOLERANCE TEST IN NORMAL SUBJECTS AND IN PATIENTS WITH HEART DISEASE. <i>Circulation</i> , 1965 , 32, 223-31	16.7	65
63	Effects of changing heart rate in man by electrical stimulation of the right atrium. studies at rest, during exercise, and with isoproterenol. <i>Circulation</i> , 1965 , 32, 549-58	16.7	218
62	Studies on cardiac dimensions in intact unanesthetized man. V. Effects of nitroglycerin. <i>Circulation</i> , 1965 , 32, 767-71	16.7	143
61	Paired electrical stimulation of the heart: a physiologic riddle and a clinical challenge. <i>Circulation</i> , 1965 , 32, 677-81	16.7	19
60	ELECTROAUGMENTATION OF VENTRICULAR PERFORMANCE AND OXYGEN CONSUMPTION BY REPETITIVE APPLICATION OF PAIRED ELECTRICAL STIMULI. <i>Circulation Research</i> , 1965 , 16, 332-42	15.7	95
59	RELATIVE ROLES OF THE SYMPATHETIC AND PARASYMPATHETIC NERVOUS SYSTEMS IN THE REFLEX CONTROL OF HEART RATE. <i>Circulation Research</i> , 1965 , 16, 363-75	15.7	214
58	Effects of Aortic Regurgitation on Left Ventricular Performance. <i>Circulation</i> , 1965 , 31,	16.7	4
57	CIRCULATORY RESPONSE TO HYPOXIA IN UNANESTHETIZED DOGS WITH AND WITHOUT CARDIAC DENERVATION. <i>American Journal of Physiology</i> , 1964 , 207, 753-8		22
56	EFFECT OF HEMORRHAGIC SHOCK ON RELEASE OF NOREPINEPHRINE BY TYRAMINE. <i>American Journal of Physiology</i> , 1964 , 206, 1262-6		6
55	THE CIRCULATORY RESPONSE OF PATIENTS WITH IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS TO NITROGLYCERIN AND TO THE VALSALVA MANEUVER. <i>Circulation</i> , 1964 , 29, 422-31	16.7	114
54	DIAGNOSTIC VALUE OF THE FIRST AND SECOND DERIVATIVES OF THE ARTERIAL PRESSURE PULSE IN AORTIC VALVE DISEASE AND IN HYPERTROPHIC SUBAORTIC STENOSIS. <i>Circulation</i> , 1964 , 30, 90-100	16.7	34

53	THE STUDY OF LEFT VENTRICULAR FUNCTION IN MAN BY INCREASING RESISTANCE TO VENTRICULAR EJECTION WITH ANGIOTENSIN. <i>Circulation</i> , 1964 , 29, 739-49	16.7	250
52	STUDIES ON STARLING'S LAW OF THE HEART. IX. THE EFFECTS OF IMPEDING VENOUS RETURN ON PERFORMANCE OF THE NORMAL AND FAILING HUMAN LEFT VENTRICLE. <i>Circulation</i> , 1964 , 30, 719-27	16.7	84
51	EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS. <i>Circulation</i> , 1964 , 29, 84-98	16.7	189
50	STUDIES ON CARDIAC DIMENSIONS IN INTACT, UNANESTHETIZED MAN. IV. EFFECTS OF ISOPROTERENOL AND METHOXAMINE. <i>Circulation</i> , 1964 , 29, 186-94	16.7	41
49	Idiopathic Hypertrophic Subaortic Stenosis: II. Operative Treatment and the Results of Pre- and Postoperative Hemodynamic Evaluations. <i>Circulation</i> , 1964 , 29,	16.7	13
48	IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS. <i>Circulation</i> , 1964 , 30, SUPPL 4:3-119	16.7	156
47	IDIOPATHIC MYOCARDIAL HYPERTROPHY WITHOUT CONGESTIVE HEART FAILURE OR OBSTRUCTION TO BLOOD FLOW. CLINICAL, HEMODYNAMIC AND ANGIOCARDIOGRAPHIC STUDIES IN FOURTEEN PATIENTS. <i>American Journal of Medicine</i> , 1963 , 35, 7-19	2.4	86
46	INTERATRIAL COMMUNICATION AND LEFT ATRIAL HYPERTENSION: A CAUSE OF CONTINUOUS MURMUR. <i>Circulation</i> , 1963 , 28, 853-60	16.7	46
45	STUDIES ON THE FUNCTION OF THE ADRENERGIC NERVE ENDINGS IN THE HEART. <i>Circulation</i> , 1963 , 28, 958-69	16.7	38
44	Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine. <i>Circulation Research</i> , 1963 , 12, 264-8	15.7	71
43	The syndrome of severe mitral regurgitation with normal left atrial pressure. <i>Circulation</i> , 1963 , 27, 29-35	16.7	152
42	Uptake and metabolism of tritiated norepinephrine in the isolated canine heart. <i>Circulation Research</i> , 1963 , 12, 220-7	15.7	23
41	Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine. <i>Circulation Research</i> , 1963 , 12, 256-63	15.7	31
40	Starling's law of the heart. VII. Ventricular function in closed-chest unanesthetized dogs. <i>American Journal of Physiology</i> , 1963 , 204, 439-45		15
39	Congenital aortopulmonary septal defect. Clinical and hemodynamic findings, surgical technic, and results of operative correction. <i>Circulation</i> , 1962 , 25, 463-76	16.7	53
38	Determination of fraction of left ventricular volume ejected per beat and of ventricular end-diastolic and residual volumes. Experimental and clinical observations with a precordial dilution technic. <i>Circulation</i> , 1962 , 25, 674-85	16.7	104
37	Transseptal left heart catheterization. A review of 450 studies and description of an improved technic. <i>Circulation</i> , 1962 , 25, 15-21	16.7	195
36	Hemodynamic-phonocardiographic correlations of the fourth heart sound in aortic stenosis. <i>Circulation</i> , 1962 , 26, 92-8	16.7	46

35	The effects of surgical abolition of left-to-right shunts on the pulmonary vascular dynamics of patients with pulmonary hypertension. <i>Circulation</i> , 1962 , 26, 1270-8	16.7	43
34	Analysis of the acute circulatory effects of guanethidine and bretylium. <i>Circulation Research</i> , 1962 , 10, 83-8	15.7	25
33	Hypertrophic subaortic stenosis--a broadened concept. <i>Circulation</i> , 1962 , 26, 161-5	16.7	57
32	Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. <i>New England Journal of Medicine</i> , 1962 , 267, 650-4	59.2	373
31	Studies on digitalis. V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. <i>Circulation</i> , 1962 , 26, 166-73	16.7	91
30	Studies on Starling's law of the heart. VIII. Mechanical properties of human myocardium studied in vivo. <i>Circulation</i> , 1962 , 26, 516-24	16.7	27
29	Effects of reserpine and guanethidine on venous reflexes. <i>Circulation Research</i> , 1962 , 11, 889-94	15.7	23
28	Circulatory effects of profound hypothermia during extracorporeal circulation. <i>American Journal of Physiology</i> , 1962 , 202, 523-6		11
27	Studies on the first derivative of the ventricular pressure pulse in man. <i>Journal of Clinical Investigation</i> , 1962 , 41, 80-91	15.9	318
26	Studies on Starling's Law of the Heart. <i>Circulation</i> , 1961 , 24, 633-642	16.7	346
25	Precordial scanning. Applications in the detection of left-to-right circulatory shunts. <i>Circulation</i> , 1961 , 23, 21-9	16.7	19
24	A Hemodynamic Technic for the Detection of Hypertrophic Subaortic Stenosis. <i>Circulation</i> , 1961 , 23, 189-194	16.7	193
23	A Simplified Technic for the Detection of Patent Ductus Arteriosus and of Other Left-to-Right Shunts Originating from the Aorta. <i>Circulation</i> , 1961 , 23, 279-285	16.7	11
22	Studies on digitalis. III. The influence of triiodothyronine on digitalis requirements. <i>Circulation</i> , 1961 , 23, 376-82	16.7	57
21	Use of krypton85 for the measurement of cardiac output by the single-injection indicator-dilution technique. <i>Circulation Research</i> , 1961 , 9, 984-8	15.7	4
20	Influence of Carotid Baroreceptors and Vasoactive Drugs on Systemic Vascular Volume and Venous Distensibility. <i>Circulation Research</i> , 1961 , 9, 75-82	15.7	47
19	Left atrial and left ventricular pressures in subjects without cardiovascular disease: observations in eighteen patients studied by transeptal left heart catheterization. <i>Circulation</i> , 1961 , 24, 267-9	16.7	130
18	Studies on Starling's Law of the Heart. <i>Circulation Research</i> , 1960 , 8, 1254-1263	15.7	74

17	Left Heart Catheterization by the Transeptal Route. <i>Circulation</i> , 1960 , 22, 927-934	16.7	101
16	Intracardiac injection of radioactive krypton. Clinical applications of new methods for characterization of circulatory shunts. <i>Circulation</i> , 1960 , 21, 1126-33	16.7	27
15	A new technic for left ventricular angiocardiology and transeptal left heart catheterization. <i>American Journal of Cardiology</i> , 1960 , 6, 1062-1064	3	185
14	Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction. <i>Circulation</i> , 1959 , 20, 181-9	16.7	144
13	Detection of pulmonic and tricuspid valvular regurgitation by means of indicator solutions. <i>Circulation</i> , 1959 , 20, 561-8	16.7	34
12	Supravalvular aortic stenosis: clinical, hemodynamic and pathologic observations. <i>Circulation</i> , 1959 , 20, 1003-10	16.7	99
11	A Simplified indicator-dilution technic for the localization of left-to-right circulatory shunts. An experimental and clinical study of intravenous injection with right heart sampling. <i>Circulation</i> , 1959 , 20, 875-80	16.7	19
10	Transeptal left atrial puncture; new technique for the measurement of left atrial pressure in man. <i>American Journal of Cardiology</i> , 1959 , 3, 653-5	3	199
9	Origin of heart sounds as elucidated by analysis of the sequence of cardiodynamic events. <i>Circulation</i> , 1958 , 18, 971-4	16.7	22
8	Congenital aortic stenosis; clinical and hemodynamic findings, surgical technic, and results of operation. <i>Circulation</i> , 1958 , 18, 1091-104	16.7	38
7	A method for the detection and estimation of aortic regurgitant flow in man. <i>Circulation</i> , 1958 , 17, 505-11	16.7	51
6	Pulsus alternans in aortic stenosis; hemodynamic observations in 50 patients studied by left heart catheterization. <i>Circulation</i> , 1958 , 18, 64-70	16.7	28
5	The nitrous oxide test: an improved method for the detection of left-to-right shunts. <i>Circulation</i> , 1958 , 17, 284-91	16.7	41
4	Left atrial pressure pulse in mitral valve disease; a correlation of pressures obtained by transbronchial puncture with the valvular lesion. <i>Circulation</i> , 1957 , 16, 399-405	16.7	68
3	Left heart catheterization by the transbronchial route: technic and applications in physiologic and diagnostic investigations. <i>Circulation</i> , 1957 , 16, 1033-9	16.7	55
2	The Haemodynamic Effects of Circulatory Drugs in Patients with Idiopathic Hypertrophic Subaortic Stenosis. <i>Novartis Foundation Symposium</i> , 172-188		1
1	Operative Treatment in Idiopathic Hypertrophic Subaortic Stenosis: Surgical Methods and the Results of Operation. <i>Novartis Foundation Symposium</i> , 250-265		